• Amir Qaseem, Adam J Obley, Tatyana Shamliyan, Lauri A Hicks, Curtis S Harrod, Carolyn J Crandall, Clinical Guidelines Committee of the American College of Physicians, Ethan M Balk, Thomas G Cooney, J Thomas Cross, Nick Fitterman, Jennifer S Lin, Michael Maroto, Matthew C Miller, Paul Shekelle, Jeffrey A Tice, Janice E Tufte, Itziar Etxeandia-Ikobaltzeta, and Jennifer Yost.
• American College of Physicians, Philadelphia, Pennsylvania (A.Q., T.S., C.H.S.).
• Ann. Intern. Med. 2024 May 1; 177 (5): 658666658-666.

DescriptionThe American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs.MethodsThis clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications. The Clinical Guidelines Committee prioritized the following outcomes, which were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach: all-cause mortality, major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for congestive heart failure, progression of chronic kidney disease, serious adverse events, and severe hypoglycemia. Weight loss, as measured by percentage of participants who achieved at least 10% total body weight loss, was a prioritized outcome, but data were insufficient for network meta-analysis and were not rated with GRADE.Audience And Patient PopulationThe audience for this clinical guideline is physicians and other clinicians. The population is nonpregnant adults with type 2 diabetes.Recommendation 1ACP recommends adding a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control (strong recommendation; high-certainty evidence). • Use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization due to congestive heart failure. • Use a GLP-1 agonist to reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke.Recommendation 2ACP recommends against adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce morbidity and all-cause mortality (strong recommendation; high-certainty evidence).

33 keywords...

hide…